Albritton v. The Florida Department of Corrections

CourtDistrict Court, M.D. Florida
DecidedJanuary 4, 2023
Docket3:21-cv-00712
StatusUnknown

This text of Albritton v. The Florida Department of Corrections (Albritton v. The Florida Department of Corrections) is published on Counsel Stack Legal Research, covering District Court, M.D. Florida primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Albritton v. The Florida Department of Corrections, (M.D. Fla. 2023).

Opinion

UNITED STATES DISTRICT COURT MIDDLE DISTRICT OF FLORIDA JACKSONVILLE DIVISION

TIMOTHY ALBRITTON,

Plaintiff,

v. Case No. 3:21-cv-712-MMH-JBT

CENTURION OF FLORIDA, et al.,

Defendants. __________________________________

ORDER

I. Status Plaintiff Timothy Albritton, an inmate in the Florida Department of Corrections (FDOC), is proceeding on a pro se Second Amended Complaint against Centurion of Florida, LLC; Dr. E. Perez-Lugo; Errol Campbell; and Corizon Health, Inc. (Doc. 15; SAC).1 Before the Court are Defendants’ Motions to Dismiss. See Defendants Perez-Lugo, Campbell, and Centurion of Florida, LLC’s Motion to Dismiss (Doc. 52); Defendants Corizon Health, Inc. and Dr. E.

1 Based on the parties’ settlement, the Court dismissed with prejudice the claims against the other named Defendants (Florida Department of Corrections, Julie Jones, Mark Inch, Ricky D. Dixon, and Thomas Reimers). See Notice of Settlement (Doc. 47); Order (Doc. 50).

Perez-Lugo’s Motion to Dismiss the Complaint (Doc. 54).2 Defendants Corizon and Perez-Lugo also filed a Consent Notice of Filing Documents in Support of

Motion to Dismiss, which includes copies of Albritton’s relevant grievances and responses thereto (Doc. 53). The Court advised Albritton that granting a motion to dismiss would be an adjudication of the case that could foreclose subsequent litigation on the matter and gave him an opportunity to respond.

See Order (Doc. 17). Albritton responded in opposition to both Motions. See Motions in Opposition to Defendants’ Motion to Dismiss (Docs. 61, 62). II. Albritton’s SAC Albritton alleges that he was diagnosed with Hepatitis C (Hep-C or HCV)

in June 2004, while housed at South Florida Reception Center. SAC at 18. He states that between 2005 and February 2007, his Hep-C was monitored but not treated. See id. at 18-19. On February 7, 2007, Albritton “agreed to wait six months until his next clinic and new lab results before deciding if he wanted

his Hep-C treated with Pegelated Inteferon and Ribivarin.” Id. at 19. At his next appointment, “his liver enzymes were almost back to normal.” Id. From January 2009 through July 2010, Albritton’s appearance was “good” and “his

2 For the time period of September 15, 2013 to April 24, 2016, Corizon’s counsel represents Defendant Perez-Lugo. See Doc. 54 at 1 n.1; see also Notice of Appearance (Doc. 18). For claims after April 24, 2016, Centurion’s counsel represents Defendant Perez-Lugo. See Notices of Appearance (Docs. 25-27). 2 Hep-C was asymptomatic,” so the doctor did not recommend any treatment. Id. In January 2011, the FDOC transferred Albritton to Suwannee

Correctional Institution (SCI), and in June 2011, his “HCV viral load test results [were] noted as being high.” Id. at 20. On September 12, 2012, testing determined that Albritton “had genotype 3a.”3 Id. In December 2014, Albritton’s medical records reflect that his Hep-C was “‘well controlled.’” Id.

According to Albritton, in March 2015, his blood test revealed that “his Hep-C was detected at over 29 million virus per IU/ml.” Id. Albritton’s medical records show that on May 26, 2015, his “Hep-C lab results were high and [he] was requesting Inteferon drug therapy.” Id. Albritton’s request, however, was

denied, because “his Hep-C was allegedly controlled.” Id. Tests revealed in September 2015 that Albritton’s “liver enzymes were elevated,” but medical staff at SCI continued to deny his requests for Interferon drug therapy from January 2016 to November 2017, while documenting “that his Hep-C was

‘controlled’ and HCV [wa]s ‘Good.’” Id. at 20-21. “However on [Albritton’s] November 25th, 2017 blood test it was found that his liver fibrosis score [wa]s 0.65, fibrosis Stage [wa]s an F3, advanced fibrosis, severe activity.” Id. at 21; see id. at 24 (alleging that in August, September, and December 2017, testing

3 Later in the SAC, Albritton alleges that on March 12, 2010, he was diagnosed with Hep-C Genotype 1A, “a more severe type of the viral disease and that may be associated with decreased responsiveness to therapy.” SAC at 23. 3 showed Albritton had a “serious” Hep-C viral load, severe fibrosis, and cirrhosis). Medical staff still did not provide him any treatment, and on May 7,

2018, staff indicated that his Hep-C was “‘good/stable.’” Id. at 21. Albritton completed lab tests on August 8, 2018, to determine his viral load. Id. On August 13, 2018, his records show “he was a F-3” and he again requested treatment. Id. He finally began a treatment protocol on September

7, 2018. Id.4 On December 12, 2019, an ultrasound showed that Albritton’s spleen was mildly enlarged, and on June 5, 2019, an ultrasound showed “mi[l]dly increased echotexture of the liver which may represent hepatic steatosis. Borderline enlarged Spleen.” Id. at 21, 22.

Albritton alleges that due to the FDOC, Corizon, and Centurion failing to provide “the well known proper level of medical care for Hep-C . . . in a timely manner,” he may be “near very possible fatal liver disease.” Id. at 22. He asserts that he has “compensated cirrhosis, level 4 fibrosis, and in the future

possible decompensated cirrhosis and liver cancer.” Id. at 23; see id. at 26 (“The denial of care, in favor of profit[,] has resulted in [Albritton’s] torment and sorrow and irreparable liver damage, and possible early loss of life.”). Albritton also states that he is “hopefully[] cured of the viral infection” after receiving

4 Albritton wrote “December 7, 2019,” as the date he began treatment, but this appears to be a scrivener’s error as he later notes that he received treatment from September 7, 2018 to December 7, 2018. SAC at 29. 4 treatment but that he “is still an F4 on the METAVIR scale and has compensated cirrhosis of his liver.” Id. at 26.

Albritton contends that the FDOC, Corizon, and Centurion “had a policy, practice, and custom established by prior litigation of not providing [direct- acting antiviral (DAA(s))] drugs to inmates with chronic HCV.” Id. at 27; see also id. at 23 (alleging that “Corizon and Centurion utilized a simple policy and

practice to deny care by institutional physicians,” which “was then ratified by” the FDOC Secretary). Albritton contends that Corizon’s and Centurion’s delay and “denial of the well known proper level of medical care,” which was prescribing DAAs, “was the proximate cause of the irreparable damage to [his]

liver.” Id. at 3-4, 5; see id. at 26 (“Defendants Corizon and Centurion’s deliberate choice to ignore the requirement of [Albritton’s] care by not administering DAA[]s until 12-07-2018 when DAAs were available in 2013 was a ‘regulatory measure.’”).

He asserts that Defendant Perez-Lugo, as the Chief Health Officer, “specifically denied and delayed [Albritton’s] treatment with the well known proper level of medical treatment for the disease Hepatitis-C [(DAAs)], known since 2014.” Id. at 6. As to Defendant Campbell, Albritton alleges that

Campbell, as the Medical Director, assisted “in setting the rules, supplied by e-mail memos, which will be obtained through discovery,” directing the Chief 5 Health Officers at FDOC institutions “to delay and thus deny [Albritton] and all other Hep-C infected FDOC inmates the proper well known level of medical

treatment.” Id. at 9. Albritton contends that both Perez-Lugo and Campbell concealed necessary information from the Federal Bureau of Prisons and/or the Center for Disease Control regarding Hep-C treatment with DAAs to foreclose Albritton from finding out about the seriousness of his disease. Id. at 6, 9.

Albritton asserts one cause of action against Defendants Centurion and Corizon – an “Eighth Amendment Monell[5] Claim.” Id. at 37.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

William Robinson v. United States
327 F. App'x 816 (Eleventh Circuit, 2007)
Rozar v. Mullis
85 F.3d 556 (Eleventh Circuit, 1996)
GJR Investments, Inc. v. County of Escambia
132 F.3d 1359 (Eleventh Circuit, 1998)
Tannenbaum v. United States
148 F.3d 1262 (Eleventh Circuit, 1998)
Anne C. Lotierzo v. A Woman's World Medical Center
278 F.3d 1180 (Eleventh Circuit, 2002)
Cottone v. Jenne
326 F.3d 1352 (Eleventh Circuit, 2003)
Sandra Jackson v. BellSouth Telecommunications
372 F.3d 1250 (Eleventh Circuit, 2004)
Roderic R. McDowell v. Pernell Brown
392 F.3d 1283 (Eleventh Circuit, 2004)
Turner v. Burnside
541 F.3d 1077 (Eleventh Circuit, 2008)
Monell v. New York City Dept. of Social Servs.
436 U.S. 658 (Supreme Court, 1978)
Swierkiewicz v. Sorema N. A.
534 U.S. 506 (Supreme Court, 2002)
Woodford v. Ngo
548 U.S. 81 (Supreme Court, 2006)
Erickson v. Pardus
551 U.S. 89 (Supreme Court, 2007)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Jones v. Bock
549 U.S. 199 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Randall v. Scott
610 F.3d 701 (Eleventh Circuit, 2010)
Parzyck v. Prison Health Services, Inc.
627 F.3d 1215 (Eleventh Circuit, 2010)
Howell v. Evans
922 F.2d 712 (Eleventh Circuit, 1991)

Cite This Page — Counsel Stack

Bluebook (online)
Albritton v. The Florida Department of Corrections, Counsel Stack Legal Research, https://law.counselstack.com/opinion/albritton-v-the-florida-department-of-corrections-flmd-2023.